Evaluation of Hypersensitivity Reactions to Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh in Shoulder Surgery

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe University of Texas Health Science Center, Houston

About this trial

The purpose of this study is to document the incidence of allergic contact dermatitis (ACD) to silk fibroin and 2-octyl cyanoacrylate mesh dressings after open shoulder surgery, to identify differences in clinic utilization for complications related to silk fibroin and 2-octyl cyanoacrylate mesh dressings and to collect patient reported outcome measures (PROMs) related to patient comfort and satisfaction for silk fibroin and 2-octyl cyanoacrylate mesh dressings.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

open shoulder procedure with Dr. James Gregory or Dr. Robert Fullick.

Disqualifiers

Prior documented medical adhesive contact allergy.

Negative pressure wound dressings.

Any procedure involving a wound problem at the planned surgical site.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Silk fibroin (SYLKE)

    Device

    SYLKE dressing will be placed in a sealed envelope, which will be opened by the operative surgeon during wound closure and placed on the closed wound. 2 week and 6 week postoperative appointments will include a standard postoperative examination that will evaluate and remove the dressing, as well as examine and document a physical examination of the surgical wound.

  • 2-octyl cyanoacrylate mesh (Dermabond PRINEO)

    Device

    Dermabond PRINEO dressing will be placed in a sealed envelope, which will be opened by the operative surgeon during wound closure and placed on the closed wound. 2 week and 6 week postoperative appointments will include a standard postoperative examination that will evaluate and remove the dressing, as well as examine and document a physical examination of the surgical wound.

Treatment groups

350 Participants
are divided into 2 treatment groups
Group A: SYLKE® Adhesive Wound ClosureExperimental treatment 1 intervention
Group B: DERMABOND™ PRINEO™ Skin Closure SystemActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Number of participants with allergic contact dermatitis (ACD) to dressings as assessed by clinical examination

ACD will be diagnosed as erythema, with or without weeping or pruritus, in a geometric border at the surgical site and in the absence of fluctuance or purulence

Time frame
at the time of dressing removal, which is about 10-14 days after the operation

Secondary outcomes

1

Clinic utilization will be defined as the total number of additional patient communications or visits regarding dressings or wound complications

This will include telephone calls, electronic messages, additional office visits and additional ER visits.

Time frame
6 weeks after the operation
2

Patients comfort as assessed by question 6 on the wound experience questionnaire

This is scored from 0(very uncomfortable) to 10 (very comfortable)

Time frame
2 weeks after the operation
3

Patients satisfaction as assessed by question 7 on the wound experience questionnaire

This is scored from 0(very dissatisfied) to 10 (very satisfied)

Time frame
2 weeks after the operation

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: